Overview
Rubella is an acute, contagious disease caused by the rubella virus, a single‑stranded RNA virus of the Togaviridae family. Transmission occurs primarily through respiratory droplets, and the incubation period averages 14‑21 days. About 50 % of infections are asymptomatic, which contributes to silent spread, especially in school‑aged children. When symptoms do appear, they typically begin with low‑grade fever, sore throat, and malaise, followed by a maculopapular rash that starts on the face and spreads downward over three days—hence the historical name “three‑day measles.” The rash is pink‑ish, not as bright as that of measles, and may be mildly pruritic. Posterior cervical and post‑auricular lymph nodes often enlarge and can remain swollen for several weeks. In adolescents and adults, arthralgia—particularly of the small joints of the hands—can be prominent and may persist for weeks.Although rubella is usually self‑limiting, it can lead to serious complications. Hemorrhagic manifestations, orchitis (testicular swelling), encephalitis, and peripheral neuropathies have been reported, though they are rare. The most consequential risk is congenital rubella syndrome (CRS) when a woman contracts the virus during the first trimester. CRS can cause cataracts, sensorineural deafness, cardiac defects (most commonly patent ductus arteriosus), and neurodevelopmental delays. The risk of CRS drops dramatically after the 20th week of gestation, but early infection remains a public health priority.
History/Background
The disease was first described in the 18th century, but it earned the name German measles after German physicians Friedrich Heine and Robert Koch distinguished it from measles in the 1860s. The term “rubella” (Latin for “little red”) was introduced by Hippocrates’s later followers and formally adopted in medical literature by the early 20th century. The first rubella vaccine—a live‑attenuated strain (RA 27/3)—was developed in the United States in the 1960s by Paul Parkman and colleagues at the National Institutes of Health. Widespread immunization began in the 1970s, and the World Health Organization (WHO) launched a global rubella elimination initiative in 1999, leading to dramatic declines in CRS worldwide.Key Information
- Etiology: Rubella virus, Togavirus genus, enveloped, icosahedral capsid. - Transmission: Respiratory droplets, direct contact with infected secretions; contagious 1 day before to 7 days after rash onset. - Incubation: 14‑21 days (average 17 days). - Clinical features: Low‑grade fever, lymphadenopathy, maculopapular rash (3 days), arthralgia (adults), mild conjunctivitis. - Complications: Encephalitis, orchitis, thrombocytopenia, CRS (if infection < 12 weeks gestation). - Diagnosis: Clinical assessment; confirmed by serology (rubella‑specific IgM/IgG) or RT‑PCR from throat swabs or urine. - Prevention: Two‑dose MMR (measles‑mumps‑rubella) vaccine at 12‑15 months and 4‑6 years; vaccine efficacy ≈ 97 % after two doses. - Management: Supportive care (antipyretics, hydration); no specific antiviral therapy. Pregnant women with exposure should receive rubella‑immune globulin only in limited circumstances and must be monitored closely. - Public health: Routine childhood vaccination has led to > 99 % reduction in CRS in countries with > 95 % coverage. Outbreaks still occur in under‑immunized communities, underscoring the need for continued surveillance and catch‑up campaigns.When to seek professional care: Anyone with a rash and fever who is pregnant, planning pregnancy, or has a compromised immune system should contact a health provider promptly. Persistent joint pain, neurological symptoms, or signs of bleeding also warrant immediate evaluation.
